- Conditions
- Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Autoimmune
- Interventions
- veltuzumab
- Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Riverdale, Georgia • Tucker, Georgia + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–232
of 232
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 16
- States / cities
- Atlanta, Georgia • Dunwoody, Georgia • Fort Wayne, Indiana + 12 more
- Conditions
- Post Thrombotic Syndrome, Deep Vein Thrombosis
- Interventions
- Fitbit, 30-minute education session
- Device · Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 7 Years to 21 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Acute Ischemic Stroke, Thrombotic Disease
- Interventions
- DS-1040b, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 16
- States / cities
- Mobile, Alabama • Los Angeles, California • Colorado Springs, Colorado + 13 more
- Conditions
- Thrombotic Thrombocytopenic Purpura
- Interventions
- Danazol
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
- Interventions
- ianalumab, thrombopoietin receptor agonist (TPO-RA)
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 19
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Torrance, California + 16 more
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Bentonville, Arkansas • Washington D.C., District of Columbia • Fort Wayne, Indiana + 2 more
- Conditions
- Hemolytic Uremic Syndrome
- Interventions
- SYNSORB Pk, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 26
- States / cities
- Denver, Colorado • Wilmington, Delaware • Atlanta, Georgia + 23 more
- Conditions
- Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplant
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 4 Weeks and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Akron, Ohio • Salt Lake City, Utah
- Conditions
- Hereditary Spherocytosis, Idiopathic Thrombocytopenic Purpura
- Interventions
- Single Incision Splenectomy, Laparoscopic Splenectomy
- Procedure
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 1 Year to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Atrial Fibrillation, Stroke, Stroke, Cardiovascular, Vascular Cognitive Impairment, Strokes Thrombotic, Stroke, Ischemic
- Interventions
- Cardiac and Brain MRI
- Device
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Cerebrovascular Accident, Hypertension
- Interventions
- aspirin, clopidogrel, Target of Blood Pressure, placebo
- Drug · Other
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 3,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 39
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 32 more
- Conditions
- Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
- Interventions
- Placebo, SHP655, Standard of Care
- Other · Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
- Conditions
- Thrombotic Microangiopathies
- Interventions
- Defibrotide
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
- Interventions
- anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
- Drug · Procedure
- Lead sponsor
- Fairview University Medical Center
- Other
- Eligibility
- 1 Year to 55 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Idiopathic Thrombocytopenia Purpura
- Interventions
- Not listed
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- New York, New York